R Arnon

Summary

Affiliation: Weizmann Institute of Science
Country: Israel

Publications

  1. ncbi Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate
    Ruth Arnon
    The Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
    J Neural Transm 116:1443-9. 2009
  2. ncbi Neurogenesis and neuroprotection in the CNS--fundamental elements in the effect of Glatiramer acetate on treatment of autoimmune neurological disorders
    Ruth Arnon
    The Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
    Mol Neurobiol 36:245-53. 2007
  3. ncbi Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications
    Ruth Arnon
    The Weizmann Institute of Science, P O Box 26, Rehovot 76100, Israel
    Proc Natl Acad Sci U S A 101:14593-8. 2004
  4. ncbi Peptide-based synthetic recombinant vaccines with anti-viral efficacy
    R Arnon
    Department of Immunology, Weizmann Institute of Science, Rehovot, Israel 76100
    Biologicals 29:237-42. 2001
  5. ncbi Immunomodulation by the copolymer glatiramer acetate
    Ruth Arnon
    Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel
    J Mol Recognit 16:412-21. 2003
  6. ncbi Preclinical efficacy of a virus-like particle-based vaccine against avian influenza H5N1
    Ruth Arnon
    Department of Immunology, Weizmann Institute of Science, PO Box 26 Rehovot, 76100, Israel
    Future Microbiol 4:503-5. 2009
  7. ncbi The 14-3-3 protein as a vaccine candidate against schistosomiasis
    D Schechtman
    Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
    Parasite Immunol 23:213-7. 2001
  8. ncbi Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1
    D Teitelbaum
    Department of Immunology, Weizmann Institute of Science, Rehovot, Israel 76100, USA
    Proc Natl Acad Sci U S A 96:3842-7. 1999
  9. ncbi Copolymer 1 inhibits manifestations of graft rejection
    R Aharoni
    Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
    Transplantation 72:598-605. 2001
  10. ncbi The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice
    Rina Aharoni
    Departments of Immunology and Veterinary Resources, The Weizmann Institute of Science, Rehovot 76100, Israel
    Proc Natl Acad Sci U S A 102:19045-50. 2005

Collaborators

Detail Information

Publications38

  1. ncbi Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate
    Ruth Arnon
    The Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
    J Neural Transm 116:1443-9. 2009
    ....
  2. ncbi Neurogenesis and neuroprotection in the CNS--fundamental elements in the effect of Glatiramer acetate on treatment of autoimmune neurological disorders
    Ruth Arnon
    The Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
    Mol Neurobiol 36:245-53. 2007
    ....
  3. ncbi Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications
    Ruth Arnon
    The Weizmann Institute of Science, P O Box 26, Rehovot 76100, Israel
    Proc Natl Acad Sci U S A 101:14593-8. 2004
    ..GA suppressed local lymphocyte proliferations and tumor necrosis factor alpha detrimental secretion but induced transforming growth factor beta, thus confirming the involvement of Th1 to Th2 shift in GA mode of action...
  4. ncbi Peptide-based synthetic recombinant vaccines with anti-viral efficacy
    R Arnon
    Department of Immunology, Weizmann Institute of Science, Rehovot, Israel 76100
    Biologicals 29:237-42. 2001
    ..Intranasal vaccination of mice with this construct, without the use of adjuvant, resulted in 40% protection against challenge infection...
  5. ncbi Immunomodulation by the copolymer glatiramer acetate
    Ruth Arnon
    Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel
    J Mol Recognit 16:412-21. 2003
    ..At present GA is considered a valuable first-line treatment option for patients with RRMS...
  6. ncbi Preclinical efficacy of a virus-like particle-based vaccine against avian influenza H5N1
    Ruth Arnon
    Department of Immunology, Weizmann Institute of Science, PO Box 26 Rehovot, 76100, Israel
    Future Microbiol 4:503-5. 2009
    ..The protective effect is correlated with both humoral and cellular immune responses...
  7. ncbi The 14-3-3 protein as a vaccine candidate against schistosomiasis
    D Schechtman
    Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
    Parasite Immunol 23:213-7. 2001
    ....
  8. ncbi Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1
    D Teitelbaum
    Department of Immunology, Weizmann Institute of Science, Rehovot, Israel 76100, USA
    Proc Natl Acad Sci U S A 96:3842-7. 1999
    ..These results suggest that oral administration of Cop 1 may modulate multiple sclerosis as well...
  9. ncbi Copolymer 1 inhibits manifestations of graft rejection
    R Aharoni
    Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
    Transplantation 72:598-605. 2001
    ..CONCLUSIONS: Cop 1 treatment inhibited the Th1 response to graft and induced a Th2 cytokines secretion in response to both Cop 1 and graft cells, leading to improved survival and function of the transplanted grafts...
  10. ncbi The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice
    Rina Aharoni
    Departments of Immunology and Veterinary Resources, The Weizmann Institute of Science, Rehovot 76100, Israel
    Proc Natl Acad Sci U S A 102:19045-50. 2005
    ..These results indicate that the immunomodulator GA exerts not only an antiinflammatory effect, but also enhances neuroprotection and regeneration of neural elements in the diseased brain...
  11. ncbi Modulation of the immune response in multiple sclerosis: production of monoclonal antibodies specific to HLA/myelin basic protein
    J Puri
    Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
    J Immunol 158:2471-6. 1997
    ..These Abs may be useful for treating multiple sclerosis in which reactivity to MBP is implicated. Moreover, this approach may be extended to other autoantigens and their counterpart autoimmune diseases...
  12. ncbi Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1
    D Teitelbaum
    Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel
    Proc Natl Acad Sci U S A 88:9528-32. 1991
    ..These results further establish the immunological interrelationships between Cop 1 and BP, demonstrated earlier at the T-cell level...
  13. ncbi Effect of pre-existing carrier immunity on the efficacy of synthetic influenza vaccine
    T Ben-Yedidia
    Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
    Immunol Lett 64:9-15. 1998
    ..Since prior exposure to the carrier did not result in immune suppression, we conclude that Salmonella flagellin is a suitable carrier for synthetic peptide based vaccines...
  14. ncbi Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE
    Rina Aharoni
    The Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
    J Neuroimmunol 225:100-11. 2010
    ....
  15. ncbi Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease
    Rina Aharoni
    Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel 76100
    J Pharmacol Exp Ther 318:68-78. 2006
    ....
  16. ncbi Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies
    Dvora Teitelbaum
    Department of Immunology, The Weizmann Institute of Science, P O Box 26, Rehovot 76100, Israel
    Ann N Y Acad Sci 1029:239-49. 2004
    ....
  17. ncbi Oral treatment of mice with copolymer 1 (glatiramer acetate) results in the accumulation of specific Th2 cells in the central nervous system
    Rina Aharoni
    Department of Immunology, The Weizmann Institute of Science, PO Box 26, Rehovot 76100, Israel
    J Neuroimmunol 126:58-68. 2002
    ....
  18. ncbi Transplanted myogenic progenitor cells express neuronal markers in the CNS and ameliorate disease in experimental autoimmune encephalomyelitis
    Rina Aharoni
    The Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
    J Neuroimmunol 215:73-83. 2009
    ..The therapeutic potential of myogenic progenitor cells was demonstrated by amelioration of clinical symptoms and reduced mortality in EAE mice, as well as by expression of IL-10, TGF-beta, and the neurotrophin-BDNF...
  19. ncbi Therapeutic vaccines: realities of today and hopes for the future
    Michael Sela
    Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel
    Drug Discov Today 7:664-73. 2002
    ..All of these efforts are based on the therapeutic vaccine being closely related chemically to the etiological agent that causes the disease...
  20. ncbi Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy
    D Teitelbaum
    Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
    Mult Scler 9:592-9. 2003
    ..These results are consistent with the findings that the therapeutic effect of GA is not affected by GA reactive antibodies and is sustained upon long term treatment...
  21. ncbi Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis
    Rina Aharoni
    Departments of Immunology and Veterinary Resources, The Weizmann Institute of Science, Rehovot 76100, Israel
    Proc Natl Acad Sci U S A 105:11358-63. 2008
    ....
  22. ncbi Linkage between immunomodulation, neuroprotection and neurogenesis
    Rina Aharoni
    Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
    Drug News Perspect 22:301-12. 2009
    ..Currently employed immunomodulatory treatments and their ability to induce neuroprotection, tissue repair and neurogenesis are also presented...
  23. ncbi The therapeutic effect of glatiramer acetate in a murine model of inflammatory bowel disease is mediated by anti-inflammatory T-cells
    Rina Aharoni
    Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel
    Immunol Lett 112:110-9. 2007
    ....
  24. ncbi The therapeutic effect of TV-5010 in a murine model of inflammatory bowel disease -- Dextran induced colitis
    Rina Aharoni
    Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel
    Int Immunopharmacol 8:1578-88. 2008
    ..Thus, TV-5010 is effective in the suppression of experimental colitis similarly to GA, with the advantage of less frequent administration, possibly via immunomodulation at the site of pathological damage...
  25. ncbi Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis
    Rina Aharoni
    Department of Immunology, The Weizmann Institute of Science, Rehovot, 76100, Israel
    J Neurosci 25:8217-28. 2005
    ..This suggests a direct linkage between immunomodulation, neurogenesis, and an in situ therapeutic consequence in the CNS...
  26. ncbi Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ
    Rina Aharoni
    Department of Immunology, The Weizmann Institute, Rehovot 76100, Israel
    Proc Natl Acad Sci U S A 100:14157-62. 2003
    ....
  27. ncbi Combined treatment of glatiramer acetate and low doses of immunosuppressive drugs is effective in the prevention of graft rejection
    Rina Aharoni
    The Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
    Int Immunopharmacol 5:23-32. 2005
    ....
  28. ncbi Therapeutic effect of the immunomodulator glatiramer acetate on trinitrobenzene sulfonic acid-induced experimental colitis
    Rina Aharoni
    Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
    Inflamm Bowel Dis 11:106-15. 2005
    ....
  29. ncbi Acetylcholinesterase of Schistosoma mansoni--functional correlates. Contributed in honor of Professor Hans Neurath's 90th birthday
    R Arnon
    Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
    Protein Sci 8:2553-61. 1999
    ..S. mansoni AChE is thus demonstrated to be a functional protein, involved in multifaceted activities, which can serve as a suitable candidate for diagnostic purposes, vaccine development, and drug design...
  30. ncbi Expression and immunolocalization of the 14-3-3 protein of Schistosoma mansoni
    D Schechtman
    Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
    Parasitology 123:573-82. 2001
    ..The possible role of the 14-3-3 protein in the genital organs is discussed...
  31. ncbi Glatiramer acetate (Copaxone) regulates nitric oxide and related cytokine secretion in experimental autoimmune encephalomyelitis
    Basak Kayhan
    Department of Immunology, The Weizmann Institute of Science, PO Box 26, Rehovot 76100, Israel
    Immunol Lett 88:185-92. 2003
    ..On the other hand, the secretion level of NO modulating cytokines IL-10 and IL-13 was significantly augmented. The correlation between these findings and the therapeutic effect of GA is discussed...
  32. ncbi Beneficial effect of glatiramer acetate treatment on syndecan-1 expression in dextran sodium sulfate colitis
    Doron Yablecovitch
    Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel
    J Pharmacol Exp Ther 337:391-9. 2011
    ..GA may be applied as a novel drug for IBD, shifting treatment from immunosuppression toward immunomodulation...
  33. ncbi Immunization with influenza virus hemagglutinin globular region containing the receptor-binding pocket
    Sung Ho Jeon
    Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
    Viral Immunol 15:165-76. 2002
    ..Interestingly, the combined DNA priming-protein boosting immunization regimen did not induce protection against viral challenges even though it led to significant humoral immune responses similar to that induced by the peptide vaccine...
  34. ncbi Old and new vaccine approaches
    Ruth Arnon
    Department of Immunology, The Weizmann Institute, PO Box 26, 76100 Rehovot, Israel
    Int Immunopharmacol 3:1195-204. 2003
    ..4) Therapeutic vaccines, based on all of the above approaches, may be applied for chronic or long-term infections, or for noninfectious diseases including autoimmune diseases, various neurological disorders, allergy and cancer...
  35. ncbi Flagella as a platform for epitope-based vaccines
    Tamar Ben-Yedidia
    Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
    Isr Med Assoc J 8:316-8. 2006
  36. ncbi A DNA aptamer prevents influenza infection by blocking the receptor binding region of the viral hemagglutinin
    Sung Ho Jeon
    Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel
    J Biol Chem 279:48410-9. 2004
    ..The mode of action of this aptamer is by blocking the binding of influenza virus to target cell receptors and consequently prevention of the virus invasion into the host cells...
  37. ncbi Towards an epitope-based human vaccine for influenza
    Tamar Ben-Yedidia
    Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
    Hum Vaccin 1:95-101. 2005
    ..Intranasal immunization in all these animal models led to effective protection against challenge infection with different strains of influenza virus...
  38. ncbi Epitope-based vaccine against influenza
    Tamar Ben-Yedidia
    BiondVax Pharmaceuticals Ltd, Ness Ziona, Israel
    Expert Rev Vaccines 6:939-48. 2007
    ..The vaccine, activating both the humoral and cellular arms of the immune response, induces long-lasting protection against many strains of the influenza virus. Consequently, it is expected to protect against future strains as well...